4th Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$610,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Prescription Drug Costs. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. 180-Day Exclusivity. S.1114: Expanding Access to Low-Cost Generics Act of 2023. H.R.5461/S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act. Labeling of Generic Drugs and Biosimilars. H.R.4134/S.2886: Updated Drug Labeling for Patient Safety Act. Hickenlooper Safe Harbor for Skinny Labeling. Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. H.R.3839/S.775: Increasing Transparency in Generic Drug Applications Act. S.2510: RAPID Reserve Act. Drug Shortages. Stop Drug Shortages Act of 2023. H.R.405: Essential Medicines Strategic Stockpile Act of 2023. S.2305: Biosimilar Red Tape Eliminations Act. FDA Inspections. Process issues regarding third-party contract to assess drug quality. Inflation Reduction Act (IRA) Implementation. H.R.3561: PATIENT Act of 2023. H.R.3793: Ensuring Access to Lifesaving Drugs Act of 2023. H.R.1503/S.2916: Prescription Information Modernization Act of 2023. H.R.2880: Protecting Patients Against PBM Abuses Act.

LobbyistCovered position, as disclosed
CRAIG BURTON —
KARIN HESSLER —
ILHAAM JAFFER —
PETER KELBEL —
KATHERINE RAAB —

Contacted: Centers For Medicare and Medicaid Services (CMS); Office of Science & Technology Policy (OSTP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Congressional Budget Office (CBO); Drug Enforcement Administration (DEA)

Bills named: S. 2780 (118th), S. 775 (118th), S. 2510 (118th), H.R. 2880 (118th), S. 2886 (118th), S. 1114 (118th), S. 2916 (118th), H.R. 3839 (118th), H.R. 4134 (118th), S. 2305 (118th), H.R. 405 (118th), H.R. 5429 (118th), S. 2129 (118th), H.R. 3561 (118th), H.R. 5461 (118th), H.R. 3793 (118th), H.R. 1503 (118th)

Medicare/Medicaid MMM

Medicare Part D Reform. Medicare Part D Program and Generic Drugs. H.R.5461/S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2023. Medicare Reimbursement for Biosimilars. H.R.1352: Increasing Access to Biosimilars Act of 2023 Medicaid Rebate Penalty. Inflation Reduction Act (IRA) Implementation. Guthrie Bill Eliminating Medicaid Generics Penalty.

LobbyistCovered position, as disclosed
CRAIG BURTON —
KARIN HESSLER —
ILHAAM JAFFER —
PETER KELBEL —
KATHERINE RAAB —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1352 (118th), S. 2129 (118th), H.R. 5461 (118th)

Copyright/Patent/Trademark CPT

Skinny Labeling. Hickenlooper Safe Harbor for Skinny Labeling. REMEDY Act. IPR Amendments. H.R.4370/S.2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. Patent Listings in Orange Book. S.150: Affordable Prescriptions for Patients Act of 2023. S.2140: Patent Eligibility Restoration Act of 2023.

LobbyistCovered position, as disclosed
KARIN HESSLER —
PETER KELBEL —
KATHERINE RAAB —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2140 (118th), S. 2220 (118th), S. 150 (118th), H.R. 4370 (118th)

Budget/Appropriations BUD

FDA Funding. Appropriations. Continuing Resolution.

LobbyistCovered position, as disclosed
KARIN HESSLER —
ILHAAM JAFFER —
KATHERINE RAAB —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Trade (domestic/foreign) TRD

General Trade Issues. Drug Supply Chain.

LobbyistCovered position, as disclosed
KARIN HESSLER —
ILHAAM JAFFER —
KATHERINE RAAB —

Contacted: SENATE; White House Office; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.